| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
1 Rearrangement Display Characteristic Genetic Alterations
**||
From the Functional Genomic Unit,* the CNRS UMR 8125 Bioinformatics Unit, the Commissariat à l’Energie Atomique LRC-29V, and the Departments of Clinical Biology,|| Nuclear Medicine,** Pathology,¶ and Biostatistics and Epidemiology, Institut Gustave-Roussy, Villejuif Cedex, France
Follicular thyroid carcinomas (FTC) arise through oncogenic pathways distinct from those involved in the papillary histotype. Recently, a t(2;3)(q13;p25) rearrangement, which juxtaposes the thyroid transcription factor PAX8 to the peroxisome proliferator-activated receptor (PPAR) 
1, was described in FTCs. In this report, we describe gene expression in 11 normal tissues, 4 adenomas, and 8 FTCs, with or without the PAX8-PPAR1 translocation, using custom 60-mer oligonucleotide microarrays. Results were confirmed by quantitative real-time polymerase chain reaction of 65 thyroid tissues and by immunohistochemistry. Statistical analysis revealed a pattern of 93 genes discriminating FTCs, with or without the translocation, that were morphologically undistinguishable. Although the expression of thyroid-specific genes was detectable, none appeared to be differentially regulated between tumors with or without the translocation. Differentially expressed genes included genes related to lipid/glucose/amino acid metabolism, tumorigenesis, and angiogenesis. Surprisingly, several PPAR target genes were up-regulated in PAX8-PPAR-positive FTCs such as angiopoietin-like 4 and aquaporin 7. Moreover many genes involved in PAX8-PPAR expression profile presented a putative PPAR-promoter site, compatible with a direct activity of the fusion product. These data identify several differentially expressed genes, such as FGD3, that may serve as potential targets of PPAR and as members of novel molecular pathways involved in the development of thyroid carcinomas.
This article has been cited by other articles:
 |
|
 |
|
  M. Eszlinger, K. Krohn, A. Kukulska, B. Jarzab, and R. Paschke Perspectives and Limitations of Microarray-Based Gene Expression Profiling of Thyroid Tumors Endocr. Rev., May 1, 2007; 28(3): 322 - 338. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. V. Reddi, B. McIver, S. K. G. Grebe, and N. L. Eberhardt The Paired Box-8/Peroxisome Proliferator-Activated Receptor-{gamma} Oncogene in Thyroid Tumorigenesis Endocrinology, March 1, 2007; 148(3): 932 - 935. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Yang, S.-H. Jo, B. Csernus, E. Hyjek, Y. Liu, A. Chadburn, and Y. L. Wang Activation of Peroxisome Proliferator-Activated Receptor {gamma} Contributes to the Survival of T Lymphoma Cells by Affecting Cellular Metabolism Am. J. Pathol., February 1, 2007; 170(2): 722 - 732. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. A. B. Knostman, S. M. Jhiang, and C. C. Capen Genetic Alterations in Thyroid Cancer: The Role of Mouse Models Vet. Pathol., January 1, 2007; 44(1): 1 - 14. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. J. Giordano, A. Y.M. Au, R. Kuick, D. G. Thomas, D. R. Rhodes, K. G. Wilhelm Jr., M. Vinco, D. E. Misek, D. Sanders, Z. Zhu, et al. Delineation, Functional Validation, and Bioinformatic Evaluation of Gene Expression in Thyroid Follicular Carcinomas with the PAX8-PPARG Translocation. Clin. Cancer Res., April 1, 2006; 12(7): 1983 - 1993. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Y. M. Au, C. McBride, K. G. Wilhelm Jr., R. J. Koenig, B. Speller, L. Cheung, M. Messina, J. Wentworth, V. Tasevski, D. Learoyd, et al. PAX8-Peroxisome Proliferator-Activated Receptor {gamma} (PPAR{gamma}) Disrupts Normal PAX8 or PPAR{gamma} Transcriptional Function and Stimulates Follicular Thyroid Cell Growth Endocrinology, January 1, 2006; 147(1): 367 - 376. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
